High-Level Highlights
- At a 5-year horizon, standard esophagectomy yielded significantly higher quality-adjusted life-years (1.74 vs 1.34) and life-years (3.11 vs 2.41) compared to active surveillance.
- Active surveillance only demonstrated a quality-of-life benefit at the 2-year mark, aligning with the initial time horizon of the SANO trial.
- Sensitivity analysis indicates that active surveillance is the preferred strategy only if the recurrence probability is below 43% or if the negative impact of surgery on quality of life is extreme and persistent.
- The study supports esophagectomy as the primary recommendation for maximizing long-term oncologic outcomes, while acknowledging surveillance as a viable path for high-risk surgical candidates.
The Dilemma of the Complete Responder
For patients with locally advanced esophageal cancer, the standard of care typically involves neoadjuvant chemoradiation (nCRT) followed by planned esophagectomy. However, a significant subset of these patients—approximately 25% to 40%—achieve a clinical complete response (cCR), where no visible tumor remains on endoscopy, biopsy, or imaging. This phenomenon has sparked a contentious debate in thoracic surgery: Is it necessary to remove the esophagus if the cancer appears to be gone?
The Surgery as Needed for Oesophageal Cancer (SANO) trial recently shook the field by suggesting that active surveillance—monitoring the patient and only operating if the cancer returns—could be a noninferior alternative to immediate surgery. While the SANO trial’s 2-year data supported the safety of this approach, clinicians have remained skeptical about the long-term trade-offs. The esophagus is a vital organ, and its removal significantly impacts quality of life (QoL); however, esophageal cancer is notoriously aggressive, and the risk of late recurrence or non-resectable systemic spread looms large over any organ-preserving strategy.
Modeling Long-Term Outcomes: Study Design
To address these long-term uncertainties, Bondzi-Simpson and colleagues developed a sophisticated decision analytical model using Markov modeling. This approach allowed the researchers to simulate the health trajectories of a cohort over a 5-year period, going beyond the shorter follow-up windows of clinical trials. The base case for the model was a 60-year-old male with good functional status and cT3N1M0 esophageal cancer who achieved a cCR after nCRT.
The model integrated probabilities of recurrence, surgical complications, and mortality derived from the SANO trial and existing oncology literature. Crucially, the researchers used “utilities”—numerical values representing the quality of life associated with different health states (e.g., life after esophagectomy vs. life under surveillance). The primary outcome was Quality-Adjusted Life-Years (QALYs), a metric that balances the quantity of life (survival) with the quality of that survival. Secondary outcomes included total life-years and sensitivity analyses to identify the “tipping points” where one strategy becomes superior to the other.
Survival vs. Organ Preservation: Key Findings
The results of the analysis provide a stark contrast between short-term gains and long-term security. At the 2-year mark, the model mirrored the SANO trial results, showing that active surveillance provided a slight advantage in QALYs (an incremental gain of approximately 15 days). This reflects the immediate avoidance of surgical morbidity and the preservation of normal swallowing and eating functions.
However, when the horizon was extended to 5 years, the data shifted dramatically in favor of esophagectomy. Patients who underwent standard surgery achieved 1.74 QALYs compared to 1.34 for those in the surveillance group—an incremental gain of 0.40 QALYs, which translates to roughly 4.8 months of life in perfect health. In terms of absolute survival, surgery provided an incremental gain of 0.70 life-years (approximately 8.4 months) over 5 years.
The discrepancy between the 2-year and 5-year outcomes is primarily driven by the cumulative risk of recurrence. In the surveillance group, the risk of local recurrence that might become unresectable or lead to metastatic disease eventually outweighs the initial QoL benefits of keeping the esophagus. Furthermore, the model found that even when esophagectomy’s negative impact on quality of life was accounted for, its ability to prevent lethal recurrences made it the statistically superior choice for long-term health.
The Tipping Point: Sensitivity Analysis
One of the most valuable aspects of this study is the sensitivity analysis, which helps clinicians identify which specific patients might actually benefit from surveillance. The model favored active surveillance only under specific conditions:
1. Lower Recurrence Risk
If the probability of cancer recurrence was less than 43%, active surveillance became the preferred strategy. This suggests that as our ability to identify “true” complete responders improves (perhaps through molecular biomarkers or advanced PET imaging), surveillance may become more viable for a select sub-population.
2. Higher Resectability of Recurrences
Surveillance was favored if the likelihood of a local recurrence being resectable was greater than 94%. In clinical practice, however, local recurrences are often more difficult to operate on after a period of surveillance due to radiation-induced fibrosis and the potential for rapid progression.
3. Severe Surgical Impact
If the quality-of-life decrement following esophagectomy was modeled as being exceptionally severe and permanent, surveillance emerged as the better choice. However, modern surgical techniques, including minimally invasive and robotic-assisted esophagectomies, have helped mitigate long-term morbidity, making this extreme scenario less common in high-volume centers.
Expert Commentary: Navigating the Trade-offs
This study highlights a classic dilemma in surgical oncology: the balance between oncologic radicality and functional preservation. While the SANO trial provided the groundwork for organ preservation, this decision analysis serves as a cautionary note. It suggests that while patients might feel better in the first two years without surgery, they may be trading away a significant chance at long-term survival.
Clinicians must engage in shared decision-making with patients, explaining that active surveillance is not a “free pass” but rather a calculated risk. For a 60-year-old patient with a long life expectancy, the 5-year survival benefit of surgery is likely the priority. Conversely, for an older patient with multiple comorbidities or a very high surgical risk, the short-term QoL benefits of surveillance might outweigh the long-term survival gains they may not live to realize.
Furthermore, the study underscores the need for more rigorous surveillance protocols. If we are to choose the surveillance route, the detection of recurrence must be early enough to allow for “salvage” esophagectomy. If the window for salvage is missed, the survival penalty is severe.
Conclusion: A Call for Individualized Precision
The findings by Bondzi-Simpson et al. reinforce esophagectomy as the preferred strategy for maximizing long-term survival and quality-adjusted life-years in clinical complete responders. However, the study does not advocate for a one-size-fits-all approach. Instead, it provides a roadmap for individualization.
Future research should focus on improving the accuracy of defining a clinical complete response. Current imaging and endoscopic biopsies have high false-negative rates. Incorporating circulating tumor DNA (ctDNA) or other liquid biopsies could potentially lower the “uncertainty” threshold, allowing clinicians to identify that <43% recurrence risk group where surveillance truly shines. Until then, surgery remains the safest bet for a cure.
References
- Bondzi-Simpson A, Gupta V, Ribeiro T, et al. Esophagectomy vs Active Surveillance in Clinical Complete Responders After Neoadjuvant Chemoradiation. JAMA Surg. 2026;161(3):275-282.
- Eyck BM, van Lanschot JJB, Hulshof MCCM, et al. Surgery versus active surveillance for oesophageal cancer: protocol for the multicentre, randomised, non-inferiority SANO trial. Trials. 2017;18(1):143.
- van der Werf A, Eyck BM, van der Gaast A, et al. Active surveillance for patients with a clinical complete response after neoadjuvant chemoradiotherapy for oesophageal cancer (SANO): a multicentre, open-label, phase 3, randomised, non-inferiority trial. Lancet Oncol. 2023.